Cerebral dopamine neurotrophic factor mRNA (CDNF mRNA)

Cerebral dopamine neurotrophic factor (CDNF) mRNA is the transcript encoding a potent neuroprotective protein that belongs to the evolutionarily conserved MANF/CDNF family. Unlike traditional neurotrophic factors such as GDNF, CDNF operates primarily by modulating the endoplasmic reticulum (ER) stress response and the unfolded protein response (UPR), which are critical pathways in the pathogenesis of protein-misfolding diseases [1][3]. In the context of Parkinson's disease, CDNF mRNA is a key therapeutic target or agent; increasing its expression in the striatum or substantia nigra has been shown to rescue degenerating dopaminergic neurons and improve motor functions in preclinical models [2][4]. Therapeutic strategies currently focus on delivering CDNF mRNA via viral vectors (gene therapy) or lipid nanoparticles to ensure sustained production of the protein within the central nervous system [5]. This approach aims to provide a disease-modifying effect by addressing the underlying cellular stress and proteotoxicity rather than merely treating symptoms. Sources: [1] Lindholm, P., et al. (2007) Nature; [2] Voutilainen, M. H., et al. (2015) Journal of Comparative Neurology; [3] Airavaara, M., et al. (2012) Frontiers in Physiology; [4] Huttunen, H. J., & Saarma, M. (2019) Trends in Molecular Medicine; [5] Herantis Pharma (2023) Pipeline Overview.

Other names

ARMETL1 mRNAConserved dopamine neurotrophic factor mRNACerebral dopamine neurotrophic factor messenger RNAARMET-like protein 1 mRNA

Translation of the mRNA into functional CDNF protein, which acts as an unconventional neurotrophic factor to alleviate endoplasmic reticulum stress and protect neurons from proteotoxicity-induced apoptosis [1][2].